Evaluation of pharmacokinetic and pharmacodynamic properties of cimicoxib in fasted and fed horses

References

• Almansa C, Alfon J, de Arriba AF, Cavalcanti FL, Escamilla I, Gomez LA, Miralles A, Soliva R, Bartroli J, Carceller E, et al. Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles. Journal of Medicinal Chemistry 46, 3463–75, 2003 doi: 10.1021/jm030765s
   PubMed Web of Science ®Google Scholar
• *Anonymous. Cimalgex: EPAR - Public assessment report (EMA/CVMP/513842/2011). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/veterinary/000162/WC500109399.pdf (accessed 28 July 2014). European Medicines Agency, London, UK, 2011
   Google Scholar
• Autefage A, Palissier FM, Asimus E, Pepin-Richard C. Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis. The Veterinary Record 168, 617, 2011 doi: 10.1136/vr.d1456
   PubMed Web of Science ®Google Scholar
• *Baggot JD, Brown SA. Basis for selection of the dosage form. In: Hardee GE, Baggot JD (eds). Development and Formulation of Veterinary Dosage Forms. Pp 7–143. Marcel Dekker, New York, USA, 1998
   Google Scholar
• Bienhoff SE, Smith ES, Roycroft LM, Roberts ES. Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Veterinary Surgery 41, 336–44, 2012
   PubMed Web of Science ®Google Scholar
• Brideau C, Van Staden C, Chan CC. In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. American Journal of Veterinary Research 62, 1755–60, 2001 doi: 10.2460/ajvr.2001.62.1755
   PubMed Web of Science ®Google Scholar
• *Caron JP. Osteoarthritis. In: Ross MW, Dyson SJ (eds). Diagnosis and Management of Lameness in the Horse. Pp 655–68. Elsevier Saunders, Saint Louis, USA, 2011
   Google Scholar
• *Caron JP, Genovese RL. Principles and practices of joint disease treatment. In: Ross MW, Dyson SJ (eds). Diagnosis and Management of Lameness in the Horse. Pp 746–64. Elsevier, Philadelphia, USA, 2003
   Google Scholar
• Eastwood MA, Kay RM. An hypothesis for the action of dietary fiber along the gastrointestinal tract. The American Journal of Clinical Nutrition 32, 364–7, 1979
   PubMed Web of Science ®Google Scholar
• Ensink JM, Klein WR, Mevius DJ, Klarenbeek A, Vulto AG. Bioavailability of oral penicillins in the horse: a comparison of pivampicillin and amoxicillin. Journal of Veterinary Pharmacology and Therapeutics 15, 221–30, 1992 doi: 10.1111/j.1365-2885.1992.tb01010.x
   PubMed Web of Science ®Google Scholar
• Ensink JM, Vulto AG, Van Miert AS, Tukker JJ, Winkel MB, Fluitman MA. Oral bioavailability and in vitro stability of pivampicillin, bacampicillin, talampicillin, and ampicillin in horses. American Journal of Veterinary Research 57, 1021–24, 1996
   PubMed Web of Science ®Google Scholar
• Giorgi M, Cuniberti B, Ye G, Barbero R, Sgorbini M, Vercelli C, Corazza M, Re G. Oral administration of tepoxalin in the horse: a pharmacokinetic/pharmacodynamic study. The Veterinary Journal 190, 143–9, 2011 doi: 10.1016/j.tvjl.2010.09.013
   PubMed Web of Science ®Google Scholar
• Giorgi M, Kim TW, Saba A, Rouini MR, Yun H, Ryschanova R, Owen H. Detection and quantification of cimicoxib, a novel COX-2 inhibitor, in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. Journal of Pharmaceutical and Biomedical Analysis 83, 28–33, 2013 doi: 10.1016/j.jpba.2013.04.024
   PubMed Web of Science ®Google Scholar
• Giraudel JM, Toutain PL, Lees P. Development of in vitro assays for the evaluation of cyclooxygenase inhibitors and predicting selectivity of nonsteroidal anti-inflammatory drugs in cats. American Journal of Veterinary Research 66, 700–9, 2005 doi: 10.2460/ajvr.2005.66.700
   PubMed Web of Science ®Google Scholar
• Goodrich LR, Nixon AJ. Medical treatment of osteoarthritis in the horse–a review. The Veterinary Journal 171, 51–69, 2006 doi: 10.1016/j.tvjl.2004.07.008
   PubMed Web of Science ®Google Scholar
• Grandemange E, Fournel S, Woehrle F. Efficacy and safety of cimicoxib in the control of perioperative pain in dogs. The Journal of Small Animal Practice 54, 304–12, 2013 doi: 10.1111/jsap.12082
   PubMed Web of Science ®Google Scholar
• Gunson DE, Soma LR. Renal papillary necrosis in horses after phenylbutazone and water deprivation. Veterinary Pathology 20, 603–10, 1983 doi: 10.1177/030098588302000512
   PubMed Web of Science ®Google Scholar
• Jeunesse EC, Schneider M, Woehrle F, Faucher M, Lefebvre HP, Toutain PL. Pharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dog. BMC Veterinary Research 9, 250, 2013 doi: 10.1186/1746-6148-9-250
   PubMed Web of Science ®Google Scholar
• Kim TW, Giorgi M. A brief overview of the coxib drugs in the veterinary field. American Journal of Animal and Veterinary Sciences 8, 89–97, 2013 doi: 10.3844/ajavsp.2013.89.97
   Google Scholar
• Kim TW, Lebkowska-Wieruszewska B, Owen H, Yun HI, Kowalski CJ, Giorgi M. Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs. The Veterinary Journal 200, 77–81, 2014a doi: 10.1016/j.tvjl.2013.12.020
   PubMed Web of Science ®Google Scholar
• Kim TW, Della Rocca G, Di Salvo A, Owen H, Sgorbini M, Giorgi M. Pharmacokinetics of the novel COX-2 inhibitor cimicoxib in donkeys. Journal of Equine Veterinary Science 34, 923–5, 2014b doi: 10.1016/j.jevs.2014.02.004
   Web of Science ®Google Scholar
• Kung K, Wanner M. Bioavailability of different forms of amoxycillin administered orally to dogs. The Veterinary Record 135, 552–54, 1994
   PubMed Web of Science ®Google Scholar
• Lees P, Landoni MF, Giraudel J, Toutain PL. Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest. Journal of Veterinary Pharmacology and Therapeutics 27, 479–90, 2004 doi: 10.1111/j.1365-2885.2004.00617.x
   PubMed Web of Science ®Google Scholar
• Maitho TE, Lees P, Taylor JB. Absorption and pharmacokinetics of phenylbutazone in Welsh Mountain ponies. Journal of Veterinary Pharmacology and Therapeutics 9, 26–39, 1986 doi: 10.1111/j.1365-2885.1986.tb00009.x
   PubMed Web of Science ®Google Scholar
• *McIlwraith CW. General pathobiology of the joint and response to injury. In: McIlwraith CW, Trotter GT (eds). Joint Disease in the Horse. Pp 40–70. Saunders, Philadelphia, USA, 1996
   Google Scholar
• Murray MJ, Grodinsky C. Regional gastric pH measurement in horses and foals. Equine Veterinary Journal 21, 73–6, 1989 doi: 10.1111/j.2042-3306.1989.tb05660.x
   Google Scholar
• Pairet M, van Ryn J. Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Inflammation Research 47, 93–101, 1998 doi: 10.1007/s000110050289
   PubMed Web of Science ®Google Scholar
• Reymond N, Speranza C, Gruet P, Seewald W, King JN. Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial. Journal of Veterinary Pharmacology and Therapeutics 35, 175–83, 2012 doi: 10.1111/j.1365-2885.2011.01297.x
   PubMed Web of Science ®Google Scholar
• Rigau D, De la Cruz G, Pena J, Carbo M, Ramis I, Izquierdo I. UR-8880, a new potent COX-2 inhibitor: First administration into man to assess its tolerability, pharmacokinetics and pharmacodynamics. Annals of the Rheumatic Diseases 62, 413, 2003
   Web of Science ®Google Scholar
• Schulze JD, Peters EE, Vickers AW, Staton JS, Coffin MD, Parsons GE, Basit AW. Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. International Journal of Pharmaceutics 300, 67–75, 2005 doi: 10.1016/j.ijpharm.2005.05.004
   PubMed Web of Science ®Google Scholar
• Seibert K, Masferrer JL. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor 4, 1, 17–23, 1993
   Google Scholar
• Snow DH, Bogan JA, Douglas TA, Thompson H. Phenylbutazone toxicity in ponies. The Veterinary Record 105, 26–30, 1979 doi: 10.1136/vr.105.2.26
   PubMed Web of Science ®Google Scholar
• Sorbera LA, Ramis I. Cimicoxib. Antiarthritic, analgesic, COX-2 inhibitor. Drug of the Future 29, 325–30, 2004 doi: 10.1358/dof.2004.029.04.790967
   Web of Science ®Google Scholar
• Teng XW, Abu-Mellal AK, Davies NM. Formulation dependent pharmacokinetics, bioavailability and renal toxicity of a selective cyclooxygenase-1 inhibitor SC-560 in the rat. Journal of Pharmacy and Pharmaceutical Sciences 6, 205–10, 2003
   PubMed Web of Science ®Google Scholar
• Toutain PL, Lees P. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics 27, 467–77, 2004 doi: 10.1111/j.1365-2885.2004.00613.x
   PubMed Web of Science ®Google Scholar
• *Toutain PL, Ferran A, Bousquet-Mélou A. Species differences in pharmacokinetics and pharmacodynamics. In: Cunningham F, Elloitt J, Lees P (eds). Comparative and Veterinary Pharmacology. Pp 19–48. Springer, Berlin, DE, 2010
   Google Scholar
• Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proceedings of the National Academy of Sciences of the United States of America 96, 7563–8, 1999 doi: 10.1073/pnas.96.13.7563
   PubMed Web of Science ®Google Scholar
• Welsh JCM, Lees P, Stodulski G, Cambridge H, Foster AP. Influence of feeding schedule on the absorption of orally administered flunixin in the horse. Equine Veterinary Journal 24, 62–5, 1992 doi: 10.1111/j.2042-3306.1992.tb04776.x
   Google Scholar
• Young JM, Panah S, Satchawatcharaphong C, Cheung PS. Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflammation Research 45, 246–53, 1996 doi: 10.1007/BF02259611
   PubMed Web of Science ®Google Scholar